Masila,

I couldn't find any recorded presentations from ESC 2016 in Rome for the introduction or the discussion and summary by Stefano Del Prato and Kausik Ray.

IMO, the 8 year lead is primarily due to RVX-208/apabetalone being the only selective bromodomain-2 BET inhibitor in clinical trials right now. All other BET inhibitors are PAN inhibitors that inhibit both bromodomains 1 and 2, which may have limited applications (i.e. oncology) because of their associated side effects.

The selective nature of RVX-208/apabetalone results in a safer BET inhibitor relative to PAN inhibitors. RVX-208 has passed one Phase 1 trial (and another nearly complete), three Phase 2 trials, and is over 10 months in to a Phase 3 trial. That is where the 8 year lead comes from. Even if another company started a Phase 1 trial with their own selective BET inhibitor today, it would take many years for them to get to the point where RVX-208/apabetalone is today.

BearDownAZ